# Aclaris Therapeutics (ACRS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ACRS
## Company Profile
- Ticker: ACRS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 5.92 USD
- Market cap: 646642838.4 USD
- Last updated: 2026-08-11
## Business Overview
### Immuno-Inflammatory Drug Development
Aclaris Therapeutics develops biologic and oral therapies for immuno-inflammatory diseases. Its portfolio targets upstream cytokines and intracellular signaling pathways.
### ATI-052
ATI-052 is a long-acting bispecific antibody against TSLP and IL-4 receptor alpha in proof-of-concept studies for asthma and atopic dermatitis.
### Bosakitug
Bosakitug is an anti-TSLP monoclonal antibody in Phase 2 development for atopic dermatitis.
### ATI-2138
ATI-2138 inhibits ITK and JAK3 and is being advanced through a Phase 2b basket strategy covering multiple forms of lichen planus.
### ATI-9494
ATI-9494 is a next-generation oral ITK inhibitor approaching IND submission for broader immuno-inflammatory development.
## Why The Stock Is Moving

As of Aug 11, 2026, ACRS closed up 0.34% at $5.92. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline Phase 1b data for ATI-052 in asthma and atopic dermatitis in the second half of 2026.
- Initiation of the first part of a Phase 2b lichen-planus study of ATI-2138 in the second half of 2026.
- IND submission for ATI-9494 in the second half of 2026.
- Initiation of a Phase 2b asthma program for ATI-052 in the fourth quarter of 2026.
- Topline Phase 2 data for bosakitug in the fourth quarter of 2026.

## Recent News
- 2026-08-06 20:35 EST — [Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-receives-fast-track-designation-for-modzatinib-ati-2138-for-9a314e80) — Source: Aclaris Therapeutics
- 2026-08-06 10:59 EST — [Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2026-financial-results-and-provides--7e16687a) — Source: Aclaris Therapeutics
- 2026-05-28 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conf-a0a234d5) — Source: Aclaris Therapeutics
- 2026-05-08 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-bank-of-america-healthcare-confe-33f392b6) — Source: Aclaris Therapeutics
- 2026-05-07 10:59 EST — [Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2026-financial-results-and-provides-c-c157b37c) — Source: Aclaris Therapeutics